Answers are grounded in this paper and cite their sources.
Introduction: Cirrhosis constitutes a major burden, owing to frequent decompensations, rehospitalizations, and significant clinical implications. Current standard, symptom-targeted therapies are limited in effectiveness. Targeting the gut-liver axis as the upstream driver of decompensation, fecal microbiota transplantation (FMT) may be beneficial. Methods: Following PRISMA, we searched Scopus, ScienceDirect, PubMed, Cochrane, Embase, and ClinicalTrials.gov for studies investigating FMT for cirrhosis. Quality of randomized trials was evaluated using the Cochrane Risk-of-Bias (RoB) 2.0, nonrandomized studies using Risk Of Bias In Nonrandomised Studies-of Interventions (ROBINS-I), and case series using the Joanna Briggs Institute tool. Inverse-variance random-effects models were fitted in R 4.5.2, with between-study variance estimated by restricted maximum likelihood. Pooled risk ratios (RR) were derived from participant-level event counts for binary outcomes and Hartung-Knapp adjusted standardised mean differences (SMD) for continuous outcomes. Certainty of evidence was rated using GRADE. Results: Nine studies with 245 participants were included; 4 contributed to the quantitative synthesis. FMT reduced hepatic encephalopathy (HE) recurrence (4 comparisons, 80 participants, 16 events; RR=0.22 [95% CI: 0.08-0.62]; P =0.0040; I ²=0%) and liver-related hospitalisation [4 comparisons, 80 participants, 19 events; RR=0.29 (95% CI: 0.12-0.69); P =0.0050; I ²=0%], although the hospitalisation effect was not retained when all-cause admissions were analysed [RR=0.69 (95% CI: 0.35-1.36); P =0.28]. Serious adverse events were borderline lower with FMT [5 comparisons, 100 participants, 42 events; RR=0.54 (95% CI: 0.29-0.99); P =0.0461; I ²=13.2%], but this estimate was not robust to leave-one-out analysis. Only one serious event across all 9 studies was adjudicated as FMT-attributable. FMT did not significantly change MELD scores [SMD= −0.12 (95% CI: −0.48 to 0.24)] or serum ammonia [SMD= −0.27 (95% CI: −0.67 to 0.12)]. Certainty of evidence was low for HE recurrence and very low for all other outcomes. Conclusion: Low-certainty evidence from 4 small trials suggests that FMT may reduce HE recurrence in cirrhosis, with no signal of excess treatment-related harm. The evidence base is still limited, and future adequately powered randomised trials are still required to compare routes of administration, or to support a change in practice.
No takes yet. Share an insight, caveat, or question.
Budiman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: